Tech Company Financing Transactions

KaloBios Pharmaceuticals Funding Round

KaloBios Pharmaceuticals, based in Brisbane, secured $12 million from 5AM Ventures, Alloy Ventures and GBS Venture Partners.

Transaction Overview

Announced On
12/22/2008
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series D
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1000 Marina Blvd. 250
Brisbane, CA 94005
USA
Email Address
Overview
KaloBios (NASDAQ: KBIO) is a vertically integrated therapeutic antibody company using its proprietary antibody engineering, humaneering and expression technologies for the development of a pipeline of antibody therapeutics.
Profile
KaloBios Pharmaceuticals LinkedIn Company Profile
Social Media
KaloBios Pharmaceuticals Company Twitter Account
Company News
KaloBios Pharmaceuticals News
Facebook
KaloBios Pharmaceuticals on Facebook
YouTube
KaloBios Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Cameron Durrant
  Cameron Durrant LinkedIn Profile  Cameron Durrant Twitter Account  Cameron Durrant News  Cameron Durrant on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/22/2008: JAZD Markets venture capital transaction
Next: 12/22/2008: ONStor venture capital transaction

 

Share this article

 


About Our VC Transactions Data

Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary